LD-2 disclosure · 2nd Quarter - Report
AMGEN
Client
- Name
- AMGEN
- Description
- Biopharmaceutical manufacturer
- Location
- California · United States of America
Registrant
- Location
- Arlington, Virginia, United States of America
Lobbying activities
2 issuesHealth Issues
Food and Drug Administration Simple Reauthorization Act of 2022 (S. 4535, FDASRA), S.4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA) and the Food And Drug Amendments (HR 7667) - accelerated approval provisions - prescription drug and biosimilars user fee agreements - importation of prescription drugs - prescription drug pricing and access issues (Sanders amendments) 340B expansion generally
LobbyistsJEANNE HAGGERTY
TargetedSENATE · HOUSE OF REPRESENTATIVES
Medicare/Medicaid
H.R. 5376 - Build Back Better Act - drug pricing provisions S. 1943, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021
LobbyistsJEANNE HAGGERTY
TargetedSENATE